相关实验视频

Updated: Mar 8, 2026

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

按需的微质细胞在阿尔茨海默病中提供治疗有效载荷

Jessica M Thanos¹, John R Lukens¹

¹Center for Brain Immunology and Glia (BIG), Department of Neuroscience, University of Virginia, Charlottesville, VA, USA; Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA; Brain Immunology and Glia Graduate Training Program, University of Virginia, Charlottesville, VA, USA.

|June 6, 2025

概括

在小鼠模型中,人类诱导的多能干细胞衍生的微质细胞被设计成表达 neprilysin,减少了阿尔茨海默病的病理学. 这种基于细胞的疗法在治疗神经系统疾病方面表现有前途.

科学领域:

神经科学是一个神经科学.
干细胞生物学干细胞生物学
神经系统疾病神经系统疾病

背景情况:

阿尔茨海默病 (AD) 的特点是粉样斑块,神经元损伤和神经炎症.
微质在阿尔茨海默氏症的发病过程中发挥着至关重要的作用.
目前的AD疗法在解决复杂的病理方面存在局限性.

研究的目的:

为了研究工程人类诱导的多能干细胞干细胞衍生微质 (iMG) 对阿尔茨海默病的治疗潜力.
评估表达分泌 neprilysin (sNEP) 的iMG 在减少AD特征中的有效性.

主要方法:

人类iPSC被分化为微质细胞 (iMG).
iMG被设计为表达分泌 neprilysin (sNEP) 在对斑块反应的 CD9 促进体的控制下.
在已建立的阿尔茨海默氏症小鼠模型中进行了工程化iMG的移植.

主要成果:

在AD小鼠模型中,工程化iMG的植入显著降低了粉样蛋白负担.
使用工程化iMG的治疗减少了神经元损伤和神经炎症.
对斑块反应的CD9促进体有效控制了sNEP在大脑中的表达.

结论:

工程人类iPSC衍生微细胞表达 neprilysin 代表阿尔茨海默病的可行的基于细胞的治疗策略.
这种方法有效地准了AD的关键病理特征,包括粉样蛋白沉积和神经炎症.
这些发现为使用基于细胞的疗法治疗神经系统疾病开辟了新的途径.

更多相关视频

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...